{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:40:48Z","timestamp":1786621248534,"version":"build-2736575974"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003061","name":"Erasmus MC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.nucmedbio.2026.109661","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:56:06Z","timestamp":1784876166000},"page":"109661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A new series of FAP inhibitors for cancer imaging based on 8-substituted (4-quinolinoyl)-glycyl-2-cyanopyrrolidine"],"prefix":"10.1016","volume":"158-159","author":[{"given":"Hanyue","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Piet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryana","family":"Handula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrina","family":"de Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Stuurman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Seimbille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2026.109661_bb0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10555-011-9340-x","article-title":"Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression","volume":"31","author":"Cirri","year":"2012","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13205246","article-title":"Cancer-associated fibroblast functions as a road-block in cancer therapy","volume":"13","author":"De","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0015","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.trecan.2022.03.001","article-title":"Targeting CAFs to overcome anticancer therapeutic resistance","volume":"8","author":"Saw","year":"2022","journal-title":"Trends Cancer"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0020","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0025","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12307-014-0153-7","article-title":"Stromal expression of fibroblast activation protein alpha (FAP) predicts platinum resistance and shorter recurrence in patients with epithelial ovarian cancer","volume":"8","author":"Mhawech-Fauceglia","year":"2015","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0030","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92232","article-title":"Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma","volume":"2","author":"Lo","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0035","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3892\/ijo.2011.906","article-title":"Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy","volume":"38","author":"Saigusa","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0040","series-title":"Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold","author":"Jansen","year":"2013"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0045","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)","volume":"57","author":"Jansen","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0050","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0055","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0060","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0065","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1007\/s00259-021-05653-0","article-title":"Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA","volume":"49","author":"Backhaus","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/ph15080958","article-title":"Automated radiosynthesis, preliminary in vitro\/in vivo characterization of OncoFAP-based radiopharmaceuticals for cancer imaging and therapy","volume":"15","author":"Bartoli","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0075","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13643-025-02835-x","article-title":"Revolutionizing cancer diagnosis and dose biodistribution: a meta-analysis of [68Ga] FAPI-46 vs. [18F] FDG imaging","volume":"14","author":"Abbasi","year":"2025","journal-title":"Syst Rev"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/ph15101292","article-title":"[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer","volume":"15","author":"Hennrich","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0090","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0095","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41416-019-0705-1","article-title":"The life cycle of cancer-associated fibroblasts within the tumour stroma and its importance in disease outcome","volume":"122","author":"D\u2019Arcangelo","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0100","doi-asserted-by":"crossref","DOI":"10.1152\/ajpgi.00075.2005","article-title":"Epithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer","volume":"289","author":"Powell","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0105","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2741\/4569","article-title":"Targeted radionuclide therapy: frontiers in theranostics","volume":"22","author":"Gallivanone","year":"2017","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0110","first-page":"1","article-title":"The molecular blueprint of targeted radionuclide therapy","author":"Primac","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0115","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/RLU.0000000000003667","article-title":"Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI04","volume":"46","author":"Kuyumcu","year":"2021","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043863","article-title":"Fibroblast activation protein inhibitor (FAPI)-based theranostics\u2014where we are at and where we are heading: a systematic review","volume":"24","author":"Sidrak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0125","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/a-1164-5667","article-title":"[68Ga]Ga-DATA5m.SA.FAPi PET\/CT: specific tracer-uptake in focal nodular hyperplasia and potential role in liver tumor imaging","volume":"59","author":"Kreppel","year":"2020","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0130","doi-asserted-by":"crossref","first-page":"8614","DOI":"10.1021\/acs.jmedchem.3c00259","article-title":"High affinity and FAP-targeted radiotracers: a potential design strategy to improve the pharmacokinetics and tumor uptake for FAP inhibitors","volume":"66","author":"Wang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0135","article-title":"Albumin binder-conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy","author":"Xu","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0140","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/thno.68182","article-title":"Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics","volume":"12","author":"Wen","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0145","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1021\/acs.bioconjchem.6c00056","article-title":"Linker chemistry in radiopharmaceutical design","volume":"37","author":"Stoddard","year":"2026","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41181-024-00283-x","article-title":"In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions","volume":"9","author":"van der Heide","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0155","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1021\/acs.bioconjchem.5c00218","article-title":"Revolutionizing solid tumor surgery with fibroblast activation protein (FAP)-targeted imaging probes for a fluorescence-guided surgery of pancreatic cancer","volume":"36","author":"Ma","year":"2025","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0160","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10967-014-3248-1","article-title":"Determination of peptide content and purity of DOTA-peptides by metal ion titration and UPLC: an alternative method to monitor quality of DOTA-peptides","volume":"302","author":"WAP","year":"2014","journal-title":"J Radioanal Nucl Chem"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13550-024-01191-6","article-title":"In vitro and ex vivo evaluation of preclinical models for FAP-targeted theranostics: differences and relevance for radiotracer evaluation","volume":"14","author":"van der Heide","year":"2024","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0170","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0175","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13550-026-01372-5","article-title":"Head-to-head comparison of [177Lu]Lu-FAP-2286 and [161Tb]Tb-FAP-2286 efficacy in a PDAC mouse model","volume":"16","author":"van der Heide","year":"2026","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121212","article-title":"First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu]Lu-DOTA.SA.FAPI and [177Lu]Lu-DOTAGA(SA.FAPI)2","volume":"14","author":"Ballal","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061889","article-title":"Novel generation of FAP inhibitor-based homodimers for improved application in radiotheranostics","volume":"15","author":"Martin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.nucmedbio.2026.109661_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29133093","article-title":"Tailoring fibroblast-activation protein targeting for theranostics: a comparative preclinical evaluation of the 68Ga- and 177Lu-labeled monomeric and dimeric fibroblast-activation protein inhibitors DOTASAFAPi and DOTAGA(SA.FAPi)2","volume":"29","author":"L\u00e4ppchen","year":"2024","journal-title":"Molecules"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805126000600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:25:46Z","timestamp":1786620346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805126000600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"alternative-id":["S0969805126000600"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109661","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A new series of FAP inhibitors for cancer imaging based on 8-substituted (4-quinolinoyl)-glycyl-2-cyanopyrrolidine","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2026.109661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109661"}}